Neurotez Inc. on NetCapital

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Raise to date: $7,656

Reporting Date: 11/17/2019

Key Stats

Minimum Raise

$10,000

Maximum Raise

$500,000

Likelihood of Max Unlikely
Start Date

08/19/2019

Stop Date

12/27/2019

Days Remaining

38

Security Type

Common Stock

Investment Minimum

$2

Deal Type

Deal to Watch


Investment Summary

Status

Active

# of Investors

Not Known

% of Minimum Raised

77%

% of Maximum Raised

2%

Dollars Per Day to Reach Max

$12,956

DPD* Committed

$85

DPD* Category

$0

DPD* All Companies

$1,357

Kingscrowd Momentum

$7,656

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Neurotez, with a post-money valuation of $22.5 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez is led by Nikolaos Tezapsidis as the President and CEO, and Wes Ashford as the Chief Medical Officer. The company has already raised $4.5 million in funding from the National Institute of Health, IRS, and New Jersey Commission of Science and Technology. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $500,000, and the proceeds will be used for the various studies, clinical trials, manufacturing, personnel costs, and debt repayment. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts.

INVEST NOW